Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07309055 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints revised (14)v3 See this version in full on ClinicalTrials.gov ↗
  2. Recruitment opened Start date changed from estimate of Dec 2025 to Mar 21, 2026 · Site details revised at 2 of 2 sites · Study title shortened, about 2 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Dec 2025 to Mar 21, 2026
    • Site details revised at 2 of 2 sites
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
Trial Details
NCT Number NCT07309055
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Adolescents With Moderate-to-severe Atopic Dermatitis
Enrollment 201 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov